Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
46 hedge funds and large institutions have $78.2M invested in Carisma Therapeutics in 2018 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 10 increasing their positions, 5 reducing their positions, and 9 closing their positions.
614% more capital invested
Capital invested by funds: $10.9M → $78.2M (+$67.2M)
211% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 9
100% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 5
70% more funds holding
Funds holding: 27 → 46 (+19)
40% more call options, than puts
Call options by funds: $1.23M | Put options by funds: $878K
1.4% more ownership
Funds ownership: 1.22% → 2.62% (+1.4%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$16.6M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$15M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$8.19M |
| 4 |
KCM
Kingdon Capital Management
New York
|
+$7.14M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$5.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$2.7M |
| 2 |
HCM
Highbridge Capital Management
New York
|
-$1.67M |
| 3 |
Millennium Management
New York
|
-$258K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$75.8K |
| 5 |
Parallax Volatility Advisers
San Francisco,
California
|
-$41K |
CARM Hedge Fund Activity: Q2 2018 in Review
46 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q2 2018, worth a combined $78.2M — up 614% from $10.9M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new CARM positions and 9 closed out — a net gain of 19 holders — while 10 added to existing stakes and 5 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $16.6M. The largest seller was Sabby Management, exiting entirely with an estimated $2.7M sold.
- 46 institutional investors held Carisma Therapeutics (CARM) as of Q2 2018, up from 27 in Q1 2018.
- Funds reported $78.2M of Carisma Therapeutics stock for Q2 2018, up 614% quarter-over-quarter.
- 28 funds opened new Carisma Therapeutics positions in Q2 2018 and 9 closed out, a net change of +19 holders.
- The largest Carisma Therapeutics buyer in Q2 2018 was Consonance Capital Management, an estimated $16.6M added.
- The largest Carisma Therapeutics seller in Q2 2018 was Sabby Management, an estimated $2.7M sold.
Based on aggregated 13F filings for Q2 2018.